The DCGI has approved Glenmark Pharmaceuticals' antiviral drug FabiFlu for treating mild to moderate COVID-19 symptoms.
On June 19, 2020, Glenmark Pharmaceuticals received approval for the manufacturing and marketing of antiviral drug Favipiravir from the Drugs Controller General of India (DCGI). The oral drug will be sold under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 symptoms.
The drug manufacturer said Favipiravir has shown clinical improvement of up to 88 percent in mild to moderate COVID-19 cases and offers a rapid reduction in viral load within four days. Additionally, the drug has been used in Russia, Japan, and China to treat COVID-19 patients and has proved successful, according to the company.
It can be used on patients with comorbid conditions such as diabetes and heart disease but is not recommended for those suffering from severe kidney or liver ailments, pregnant and lactating women.
FabiFlu tablets will be available for sale in hospitals and retail pharmacies across the country by early next week. It is to be administered under strict medical supervision and will not be available over-the-counter. It will be sold in a pack of 34 oral tablets of 200 mg each for Rs 3,500, and the cost of the 14-day treatment will be an estimated Rs 14,000.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.